Pathogenesis of cyclosporine nephropathy: roles of angiotensin II and osteopontin.
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Low-salt-diet, cyclosporine (CsA; 15 mg/kg per day)-treated rats develop striped interstitial fibrosis, arteriolar hyalinosis, and azotemia similar to the chronic nephropathy observed in humans. To examine the role of angiotensin II in this model, rats on a low-salt diet were given CsA, CsA and the angiotensin II receptor Type I antagonist Losartan (10 mg/kg per day), CsA and hydralazine/furosemide, or vehicle. At Day 35, CsA-treated rats had tubular injury, arteriolopathy of the afferent arteriole, increased expression of the monocyte-macrophage adhesive protein osteopontin, interstitial macrophage infiltration, increased interstitial transforming growth factor-beta expression, and interstitial fibrosis. This study provides new insight in both pathogenic and therapeutic aspects of CsA nephropathy. The pathogenesis of CsA nephropathy involves the expression of osteopontin by tubular epithelial cells, the level of which closely correlates with the degree of macrophage infiltration and interstitial fibrosis in all groups (r = 0.79 and 0.74, respectively; P < 0.001). Therapeutic conclusions can be drawn from the observation that both losartan and hydralazine/furosemide reduced osteopontin expression, macrophage infiltration, transforming growth factor-beta expression, and interstitial fibrosis, but did not prevent the decrease in GFR. Treatment with losartan, but not with hydralazine and furosemide, markedly reduced arteriolopathy. It was concluded that angiotensin II contributes to the vasculopathy (hyalinosis) induced by CsA. In contrast, the interstitial fibrosis mediated by CsA can be partially prevented by both an angiotensin II Type I receptor antagonist or by hydralazine and furosemide. This suggests that the interstitial fibrosis can be dissociated from the vascular effects of CsA. The beneficial effects of lowering blood pressure or vasodilation per se may be difficult to distinguish from the specific effects of angiotensin II receptor blockade.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CYCLOSPORIN A IN PATIENTS RECEIVING RENAL ALLOGRAFTS FROM CADAVER DONORS
Calne, R. Y., Thiru, S., Mcmaster, P., Craddock, G. N., White, D. J. G., Evans, D. B., Dunn, D. C., Pentlow, B. D., & Rolles, K. (1978) · The Lancet · doi:10.1016/s0140-6736(78)91970-0 · Cited by 1,002
Giachelli, C. M., Bae, N., Almeida, M., Denhardt, D. T., Alpers, C. E., & Schwartz, S. M. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116755 · Cited by 641
Self-citationRenal injury from angiotensin II-mediated hypertension.
Johnson, R. J., Alpers, C. E., Yoshimura, A., Lombardi, D., Pritzl, P., Floege, J., & Schwartz, S. M. (1992) · Hypertension · doi:10.1161/01.hyp.19.5.464 · Cited by 536
Self-citationInflammatory and immunomodulatory roles of TGF-β
Wahl, S. M., McCartney-Francis, N., & Mergenhagen, S. E. (1989) · Immunology Today · doi:10.1016/0167-5699(89)90136-9 · Cited by 449
Effect of cyclosporine administration on renal hemodynamics in conscious rats
Murray, B. M., Paller, M. S., & Ferris, T. F. (1985) · Kidney International · doi:10.1038/ki.1985.196 · Cited by 419
Sustained expression of TGF-β1 underlies development of progressive kidney fibrosis
Yamamoto, T., Noble, N. A., Miller, D. E., & Border, W. A. (1994) · Kidney International · doi:10.1038/ki.1994.122 · Cited by 405
Floege, J., Burns, M. W., Alpers, C. E., Yoshimura, A., Pritzl, P., Gordon, K., Seifert, R. A., Bowen-Pope, D. F., Couser, W. G., & Johnson, R. J. (1992) · Kidney International · doi:10.1038/ki.1992.42 · Cited by 404
Self-citationShiraga, H., Min, W., VanDusen, W. J., Clayman, M. D., Miner, D., Terrell, C. H., Sherbotie, J. R., Foreman, J. W., Przysiecki, C., & Neilson, E. G. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.1.426 · Cited by 390
Wolf, G., Mueller, E., Stahl, R. A., & Ziyadeh, F. N. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116710 · Cited by 379
Patarca, R., Freeman, G. J., Singh, R. P., Wei, F. Y., Durfee, T., Blattner, F., Regnier, D. C., Kozak, C. A., Mock, B. A., & Morse, H. C. (1989) · The Journal of experimental medicine · doi:10.1084/jem.170.1.145 · Cited by 322
Cited by
Chronic Renal Failure after Transplantation of a Nonrenal Organ
Ojo, A. O., Held, P. J., Port, F. K., Wolfe, R. A., Leichtman, A. B., Young, E. W., Arndorfer, J., Christensen, L., & Merion, R. M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021744 · Cited by 2,220
Costanzo, M. R., Costanzo, M. R., Dipchand, A., Starling, R., Anderson, A., Chan, M., Desai, S., Fedson, S., Fisher, P., Gonzales-Stawinski, G., et al. (2010) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2010.05.034 · Cited by 1,653
Calcineurin Inhibitor Nephrotoxicity
Naesens, M., Kuypers, D. R. J., & Sarwal, M. (2009) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04800908 · Cited by 1,489
Inflammation and angiotensin II
Suzuki, Y., Ruiz-Ortega, M., Lorenzo, O., Ruperez, M., Esteban, V., & Egido, J. (2003) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(02)00271-6 · Cited by 694
Molecular insights into renal interstitial fibrosis.
Eddy, A. A. (1996) · Journal of the American Society of Nephrology · doi:10.1681/asn.v7122495 · Cited by 637
Role of the Microvascular Endothelium in Progressive Renal Disease
Kang, D.-H., Kanellis, J., Hugo, C., Truong, L., Anderson, S., Kerjaschki, D., Schreiner, G. F., & Johnson, R. J. (2002) · Journal of the American Society of Nephrology · doi:10.1681/asn.v133806 · Cited by 466
Self-citationSubtle Acquired Renal Injury as a Mechanism of Salt-Sensitive Hypertension
Johnson, R. J., Herrera-Acosta, J., Schreiner, G. F., & Rodríguez-Iturbe, B. (2002) · New England Journal of Medicine · doi:10.1056/nejmra011078 · Cited by 448
Osteopontin—a molecule for all seasons
Mazzali, M., Kipari, T., Ophascharoensuk, V., Wesson, J. A., Johnson, R., & Hughes, J. (2002) · QJM: An International Journal of Medicine · doi:10.1093/qjmed/95.1.3 · Cited by 392
KANG, D.-H., HUGHES, J., MAZZALI, M., SCHREINER, G. F., & JOHNSON, R. J. (2001) · Journal of the American Society of Nephrology · doi:10.1681/asn.v1271448 · Cited by 390
Expression, roles, receptors, and regulation of osteopontin in the kidney
Xie, Y., Sakatsume, M., Nishi, S., Narita, I., Arakawa, M., & Gejyo, F. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.00032.x · Cited by 361
Agunloye, O. M., Oboh, G., Ademiluyi, A. O., Ademosun, A. O., Akindahunsi, A. A., Oyagbemi, A. A., Omobowale, T. O., Ajibade, T. O., & Adedapo, A. A. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.10.044 · Cited by 285
Essential Hypertension, Progressive Renal Disease, and Uric Acid: A Pathogenetic Link?
Johnson, R. J., Segal, M. S., Srinivas, T., Ejaz, A., Mu, W., Roncal, C., Sánchez-Lozada, L. G., Gersch, M., Rodriguez-Iturbe, B., Kang, D.-H., et al. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005010063 · Cited by 280
Johnson, R. J., Kivlighn, S. D., Kim, Y.-G., Suga, S., & Fogo, A. B. (1999) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(99)70295-7 · Cited by 267
Rodríguez-Iturbe, B., Quiroz, Y., Nava, M., Bonet, L., Chávez, M., Herrera-Acosta, J., Johnson, R. J., & Pons, H. A. (2002) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.0197.2001 · Cited by 261
Burdmann, E. A., Andoh, T. F., Yu, L., & Bennett, W. M. (2003) · Seminars in Nephrology · doi:10.1016/s0270-9295(03)00090-1 · Cited by 258
Self-citationIdentification of putative gene based markers of renal toxicity.
Amin, R. P., Vickers, A. E., Sistare, F., Thompson, K. L., Roman, R. J., Lawton, M., Kramer, J., Hamadeh, H. K., Collins, J., Grissom, S., et al. (2004) · Environmental Health Perspectives · doi:10.1289/ehp.6683 · Cited by 256
Angiotensin II blockade decreases TGF-β1 and matrix proteins in cyclosporine nephropathy
Shihab, F. S., Bennett, W. M., Tanner, A. M., & Andoh, T. F. (1997) · Kidney International · doi:10.1038/ki.1997.380 · Cited by 209
Self-citationRole of immunocompetent cells in nonimmune renal diseases
Rodríguez-Iturbe, B., Pons, H., Herrera-Acosta, J., & Johnson, R. J. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.0590051626.x · Cited by 187
Ischemic renal diseases: New insights into old entities
Meyrier, A., Hill, G. S., & Simon, P. (1998) · Kidney International · doi:10.1046/j.1523-1755.1998.00968.x · Cited by 182
Osteopontin Function in Pathology: Lessons from Osteopontin-Deficient Mice
Rittling, S. R., & Denhardt, D. T. (1999) · Nephron Experimental Nephrology · doi:10.1159/000020591 · Cited by 172
The role of osteopontin in foreign body giant cell formation
Tsai, A. T., Rice, J., Scatena, M., Liaw, L., Ratner, B. D., & Giachelli, C. M. (2005) · Biomaterials · doi:10.1016/j.biomaterials.2005.03.003 · Cited by 71
Metadata
- Authors
- Pichler, R. H., Franceschini, N., Young, B. A., Hugo, C., Andoh, T. F., Burdmann, E. A., Shankland, S. J., Alpers, C. E., Bennett, W. M., & Couser, W. G.
- Venue
- Journal of the American Society of Nephrology
- Published
- 1995-10
- Volume
- 6
- Issue
- 4
- Pages
- 1186-1196
- ISSN
- 1046-6673 (ISSN-L)
- OpenAlex
- W2098945680
- Cited by
- 256
- References
- 22
- FWCI
- 10.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.